HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Short-term efficacy evaluation of chronic pulmonary aspergillosis treated with micafangin and maintenance therapy of itraconazole].

Abstract
We evaluated both the short-and long-term efficacy of micafungin in patients with chronic pulmonary aspergillosis (CPA). We treated 26 patients with CPA, 19 with chronic necrotizing pulmonary aspergillosis (CNPA) and 7 with aspergilloma, with micafungin between February 2003 and September 2005. On completion of treatment (short-term efficacy evaluation), the efficacy rates of micafungin for CNPA and aspergilloma were 52.6% (10/19) and 71.4% (5/7), respectively, and the overall efficacy rate was 57.7% (15/26). Long-term efficacy was evaluable in 25 of 26 patients, and 15 patients, who responded favorably to micafungin, received maintenance therapy with itraconazole (200mg). In long-term efficacy evaluation, 10 patients were unchanged, but in 5 patients symptoms were exacerbated after 1.8 months (median time). This result suggests that establishing effective maintenance therapy, as well as acute-phase therapy, is important in the treatment of patients with CPA.
AuthorsShigeo Yasuda, Ryoko Ohnishi, Toshitaka Suzuki, Kimiyasu Sano, Tatuo Kato
JournalNihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society (Nihon Kokyuki Gakkai Zasshi) Vol. 47 Issue 11 Pg. 985-90 (Nov 2009) ISSN: 1343-3490 [Print] Japan
PMID19994592 (Publication Type: Journal Article)
Chemical References
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Itraconazole
  • Micafungin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents (therapeutic use)
  • Chronic Disease
  • Echinocandins (therapeutic use)
  • Female
  • Humans
  • Itraconazole (administration & dosage)
  • Lipopeptides (therapeutic use)
  • Male
  • Micafungin
  • Middle Aged
  • Pulmonary Aspergillosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: